# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $85 to $87.
In addition to evaluating the safety and performance of the EMPOWER LP as a standalone pacemaker, the trial evaluated the abili...
Sports betting app DraftKings is "terrific," Cramer says. The company recently reported Q1 revenue of $1.18 billion, up...
Mizuho Securities raises target for Boston Scientific, predicting double-digit growth in cardiology. Surge in Farapulse adoptio...
Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $85 to $90.